Eyenovia Provides Update on Phase 3 CHAPERONE Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall Street dips as rising Treasury yields outweigh software gains
- Oil prices rise $3 as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Brookline Capital Markets Downgrades Eyenovia (EYEN) to Hold
November 15, 2024 9:24 AM ESTBrookline Capital Markets analyst Kemp Dolliver downgraded Eyenovia (NASDAQ: EYEN) from Buy to Hold.
The analyst comments "EYEN announced this morning that CHAPERONEs Independent Review Committee determined that the trial failed to meet the primary efficacy endpoint. As a result, the company will... More
